Search Results
Found 1 results
510(k) Data Aggregation
(52 days)
The Hollow Fibre Membrane Oxygenator HMO 1010 is intended for use in an extracorporeal perfusion circuit to oxygenate blood and remove carbon dioxide and to temper blood during short duration cardiopulmonary bypass procedures lasting 6 hours or less.
The Hollow Fibre Membrane Oxygenator Quadrox HMO 1010 is a blood gas exchanger with integrated heat exchanger. In open heart surgery it is used in an extracorporeal perfusion circuit first to oxygenate blood and remove carbondioxide second to regulate the blood temperature during short duration cardiopulmonary bypass procedures lasting 6 hours or less.
The oxygenation system is principally based on microporous polypropylene hollow fiber membranes. The heat exchanger is made of thight polyethylene fibers. The QUADROX consists of two membrane compartments. In the first chamber of the oxygenator, sheets of heat exchanger fibers and sheets of microporous oxygenation fibers are arranged crosswise. In the second chamber only sheets of the oxygenation fibers are arranged.
Blood enters the housing via the inlet connector and is distributed into a pre-chamber. Then the blood streams through the membrane package. In the first section it is tempered and oxygenated. In the second part only oxygenation and removal of carbondioxide takes place.
Positioned and integrated at the top of the oxygenator is a de-airing membrane. This membrane is a hydrophobic membrane allowing only gaseous substances to pass through the membrane but fluids are held back. The de-airing membrane allows easier priming, deairing and elimination of air throughout the whole procedure. To prime the oxygenator the Luer cap has to be removed. It should be kept open during perfusion to eliminate air continuously.
Acceptance Criteria and Device Performance for Jostra Medizintechnik AG Hollow Fibre Membrane Oxygenator Quadrox HMO 1010
This document outlines the acceptance criteria and performance data for the Hollow Fibre Membrane Oxygenator Quadrox HMO 1010, based on the provided 510(k) summary. The device was found to be substantially equivalent to the Affinity Hollow Fiber Oxygenator by Avecor Cardiovascular, Inc.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are implicitly defined by the substantial equivalence determination to the predicate device. The performance data for the Quadrox HMO 1010 are compared to the predicate device's specifications.
| Parameter | Acceptance Criteria (Predicate Device: Affinity Hollow Fiber Oxygenator) | Reported Device Performance (Quadrox HMO 1010) |
|---|---|---|
| Membrane Type | Microporous Polypropylene Hollow Fibers | Microporous Polypropylene Hollow Fibre |
| Membrane Surface Area | $2.5 m^2$ | $1.8 m^2$ |
| Static Priming Volume | 270 ml | 250 ml |
| Recommended Blood Flow Rate | 1-7 liters/minute | 0.5-7 liters/minute |
| Maximum Water Side Pressure | 30 psi | 14 psi |
| Material of Heat Exchanger | Stainless steel | Polyethylene |
| Arterial Outlet Port | 3/8" | 3/8" |
| Venous Inlet Port | 3/8" | 3/8" |
| Arterial Sample Port | Female Luer Port | Luer-Port |
| Recirculation Port | 1/4" | 1/4" |
| Gas Inlet Port | 1/4" | 1/4" |
| Gas Outlet Port | 3/8" non-barbed | 1/4" |
| Water Ports | ½" quick disconnects | ½" Quick-Connect Fittings (Hansen) |
| Method of Sterilization | unknown | Ethylene Oxide |
| Use | Single-use device | Single-use device |
| Biocompatibility | Biocompatible and non-toxic | Biocompatible and non-toxic |
| Sterility Assurance Level (SAL) | 10-6 | 10-6 |
| EtO Residuals (Ethylene Oxide) | <25 ppm | <25 ppm |
| EtO Residuals (Ethylene Chlorohydrin) | <25 ppm | <25 ppm |
| EtO Residuals (Ethylene Glycol) | <250 ppm | <250 ppm |
| Pyrogens (EU/ml) | <20 EU/ml | <20 EU/ml |
Note: For parameters listed as "unknown" for the predicate device, the performance of the Quadrox HMO 1010 was assessed against general safety and effectiveness standards, and determined to be acceptable. The critical factor for substantial equivalence is that these differences do not raise new questions of safety or effectiveness.
2. Sample Size Used for the Test Set and Data Provenance
The document does not explicitly state the sample size for specific "test sets" in the traditional sense of a clinical study. The evaluation primarily relies on in-vitro bench testing and in-vivo animal testing. The provenance of this data is Germany, where Jostra Medizintechnik AG is located. The nature of the data is likely retrospective as it compares the new device to an existing predicate.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
This information is not provided in the summary. For device testing of this nature (bench and animal), the ground truth is established through standardized testing protocols and measurements, rather than expert consensus on diagnostic interpretation.
4. Adjudication Method for the Test Set
Adjudication methods like 2+1 or 3+1 are typically used in clinical studies involving interpretation of medical images or patient outcomes. For this type of device submission, which focuses on in-vitro and animal testing, an explicit adjudication method is not applicable or described. Performance is evaluated against objective measurements and established scientific criteria.
5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study
An MRMC comparative effectiveness study was not conducted as described in the provided summary. This type of study is more relevant for diagnostic AI devices where human reader performance is a key metric. The current submission focuses on the safety and effectiveness of a medical device (oxygenator) through physical/chemical performance and biocompatibility.
6. Standalone Performance Study
A standalone (algorithm only without human-in-the loop performance) study was not explicitly conducted. However, the in-vitro bench testing and animal testing can be considered a form of standalone performance evaluation for the device itself, independent of human interaction beyond standard operational procedures. This evaluated the device's technical specifications and functionality directly.
7. Type of Ground Truth Used
The ground truth for the device's performance was established through:
- Objective Measurements: For in-vitro bench testing (e.g., membrane surface area, priming volume, flow rates, pressure, heat exchanger performance factor, integrity testing).
- Standardized Biological Evaluation: For biocompatibility (in accordance with FDA Blue Book Memorandum - #G95-1, ISO 10993-1, and United States Pharmacopeia - XXIII), blood cell damage, sterility assurance level (SAL), EtO residuals, and pyrogen testing (Limulus Amebocyte Lysate (LAL) method).
- Physiological Outcomes: For in-vivo animal testing, though specific outcome measures are not detailed in this summary.
There is no mention of pathology or human patient outcomes data being used as ground truth for this specific application.
8. Sample Size for the Training Set
This information is not applicable or provided. The development of this medical device (oxygenator) does not involve a "training set" in the context of machine learning. The device design and manufacturing rely on engineering principles, materials science, and established medical device standards.
9. How the Ground Truth for the Training Set Was Established
As there is no "training set" in the machine learning sense for this device, this question is not applicable. The underlying principles and data used for design and manufacturing are based on scientific understanding of cardiopulmonary bypass, material properties, and regulatory standards.
Ask a specific question about this device
Page 1 of 1